Home›Screener›BLU›Profile
C
61/100

BELLUS Health

BLUChronic Cough
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

BELLUS Health (BLU) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 3[1].

Trial NCT05599191[3] evaluates BLU-5937 in Cough with a target enrollment of 825 participants. Trial NCT05600777[4] evaluates BLU-5937 in Cough with a target enrollment of 975 participants.

No Form 4 insider filings for BLU were recorded at the SEC in the past 30 days[5].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov · NCT05599191 (2025-06-10) ↗
  4. ClinicalTrials.gov · NCT05600777 (2025-10-07) ↗
  5. SEC EDGAR (2026-04-11) ↗
🔬
Clinical Trials
2
NCT05599191Cough, Refractory Chronic Cough
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05600777Cough, Refractory Chronic Cough
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Data Provenance
clinical trial2 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR